

# WisdomTree

## BioRevolution UCITS ETF - USD Acc

### Fund Investment Objective

The WisdomTree BioRevolution UCITS ETF (the "Fund") seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution ESG Screened Index (the "Index").

### Index Description

The index is designed to track performance of companies that will be significantly transformed by advancements in genetics and biotechnology (including COVID-19 vaccines). The index excludes companies which do not meet WisdomTree's ESG (environmental, social and governance) criteria.

To be included in the Index, companies must meet certain risk management criteria, as well as minimum liquidity requirements, WisdomTree's ESG screen and be issued involved in BioRevolution activities. The key sectors listed below are used as guidelines to determine if a company is primarily involved in BioRevolution Activities, including Human health, Agriculture & Food, Materials, Chemicals, & Energy and Biological Machines & Interfaces.

### Listing Information

Exchange	ISE, LSE, Xetra
Listing Currency	USD
LSE Code	WDNA
Bloomberg Code	WDNA LN
Reuters Code	WDNA.L
ISIN	IE000O8KMPM1

### Fund Information

Asset Class	Equities
Benchmark	WisdomTree BioRevolution ESG Screened Net Return Index
Replication Method	Physical, Fully Replicated
Total Expense Ratio	0.45%
Base Currency	USD
Use of Income	Accumulating
Distribution Frequency	N/A
Since Fund Inception	03/12/2021
Financial Year End	31 December
UCITS Compliant	No
ISA Eligible	Yes
SIPP Eligible	Yes
EU Savings Directive	Out of Scope
Registration	GB, DE, IT, IE, CH, NL, FI, SE, FR, LU, ES, DK
Manager	WisdomTree Management Ltd.
Investment Manager	Irish Life Investment Managers
Administrator	State Street Fund Services (Ireland) Limited
Custodian	State Street Custodial Services (Ireland) Limited

### Average Annual Total Returns (USD)

Name	QTR	YTD	1-Year	3-Year	Since Fund Inception
WDNA NAV	0.00%	-16.52%	0.00%	N/A	-13.29%

Source: WisdomTree UK, Bloomberg, as of 28/02/2022. Performance for the fund and the index is shown in the listing currency. The fund performance is given net of fees. Investors should be aware that fees have a detrimental impact on the performance of an ETF. Please note this data refers to past performance and is not an indicator for future results and should not be the sole factor of consideration when selecting a product. Performance of less than one year is cumulative.

### Potential Benefits

- The Fund offers access through direct investment in publicly listed companies, which will be significantly transformed by advancements in genetics and biotechnology (including COVID-19 vaccines).
- Focused exposure to businesses that have multi-sector genetics and biotechnology investments with strong growth characteristics and which meet WisdomTree's ESG (environmental, social and governance) criteria
- The research for the selection of companies in the Index and, subsequently, the Fund, is conducted by expert in the BioRevolution space, ensuring the portfolio remains focused and relevant
- The ETF is physically backed and UCITS compliant

### Potential Risks

- Although the Index was created to select companies with a relatively higher exposure to BioRevolution activities, there is no guarantee this objective will be achieved
- An investment in equities may experience high volatility and should be considered as a long-term investment
- Higher growth companies such as those that play a part in megatrends tend to trade at higher valuations. The investor should consider the risk that comes with higher valuations as part of any investment decision
- Investment risk may be concentrated in specific sectors, countries, companies or currencies.
- This list does not cover all risks-further risks are disclosed in the KIID and Prospectus


Investors should read the prospectus of the Issuer ("Prospectus") before investing and should refer to the section of the Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in this product.

WisdomTree.com • 1 KING WILLIAM STREET, LONDON, EC4N 7AF, T +44 20 7448 4330



# WisdomTree

## BioRevolution UCITS ETF - USD Acc



NB: Sources for all tables/charts on these pages: WisdomTree UK, Bloomberg. All data as of 28/02/2022

### Glossary

**Dividend Weighted Index:** an index that determines the weight of its constituents using the dividends paid by the security rather than another variable (the most common is Market Cap weighted indices). **Fully Replicated:** assets are invested in securities that match the constituents of the relevant index, in the same proportion. **Fundamentally Weighted Index:** an index that weights securities on the basis of factors such as dividends or earnings.

**Large Cap, Mid Cap and Small Cap:** refers to market capitalisation and is calculated by multiplying the price of a stock by the number of shares outstanding. **Listing currency:** the trading currency on the exchange. **Physical (Optimised):** assets are predominately invested in securities that are constituents of the index, but may also hold securities whose characteristics closely resemble the characteristics of the index. **Physically Backed:** securities held by the fund are the actual securities not a derivative. **Rebalance:** An index is created by applying a certain set of selection and weighting rules of countries, sectors and stocks at a certain frequency. A Rebalance is when WisdomTree re-applies its rules based selection and weighting process. **Rebalance Frequency:** The frequency by which the constituents of the index are screened and their weights changed. **Replication Method:** the method by which the fund gets exposure to the benchmark index. **Share class currency or the "NAV currency":** The currency that the fund's NAV is issued in. **Total Expense Ratio (TER):** a measure of the total costs associated with managing and operating a fund. The TER consists primarily of management fees plus other expenses such as trustee, custody and operating expenses. It is expressed as a percentage of the fund's total net asset value.

# WisdomTree

## BioRevolution UCITS ETF - USD Acc

**WDNA**

### Disclaimer

**Communications issued in the European Economic Area ("EEA"):** This document has been issued and approved by WisdomTree Ireland Limited, which is authorised and regulated by the Central Bank of Ireland.

**Communications issued in jurisdictions outside of the EEA:** This document has been issued and approved by WisdomTree UK Limited, which is authorised and regulated by the United Kingdom Financial Conduct Authority. WisdomTree Ireland Limited and WisdomTree UK Limited are each referred to as "WisdomTree" (as applicable). Our Conflicts of Interest Policy and Inventory are available on request.

**For professional clients only. Past performance is not a reliable indicator of future performance. Any historical performance included in this document may be based on back testing. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of such strategy would have been. Back tested performance is purely hypothetical and is provided in this document solely for informational purposes. Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance. The value of any investment may be affected by exchange rate movements. Any decision to invest should be based on the information contained in the appropriate prospectus and after seeking independent investment, tax and legal advice. These products may not be available in your market or suitable for you. The content of this document does not constitute investment advice nor an offer for sale nor a solicitation of an offer to buy any product or make any investment.**

An investment in exchange-traded products ("ETPs") is dependent on the performance of the underlying index, less costs, but it is not expected to match that performance precisely. ETPs involve numerous risks including among others, general market risks relating to the relevant underlying index, credit risks on the provider of index swaps utilised in the ETP, exchange rate risks, interest rate risks, inflationary risks, liquidity risks and legal and regulatory risks.

The information contained in this document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares in the United States or any province or territory thereof, where none of the issuers or their products are authorised or registered for distribution and where no prospectus of any of the issuers has been filed with any securities commission or regulatory authority. No document or information in this document should be taken, transmitted or distributed (directly or indirectly) into the United States. None of the issuers, nor any securities issued by them, have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes.

This document may contain independent market commentary prepared by WisdomTree based on publicly available information. Although WisdomTree endeavours to ensure the accuracy of the content in this document, WisdomTree does not warrant or guarantee its accuracy or correctness. Any third party data providers used to source the information in this document make no warranties or representation of any kind relating to such data. Where WisdomTree has expressed its own opinions related to product or market activity, these views may change. Neither WisdomTree, nor any affiliate, nor any of their respective officers, directors, partners, or employees accepts any liability whatsoever for any direct or consequential loss arising from any use of this document or its contents.

This document may contain forward looking statements including statements regarding our belief or current expectations with regards to the performance of certain assets classes and/or sectors. Forward looking statements are subject to certain risks, uncertainties and assumptions. There can be no assurance that such statements will be accurate and actual results could differ materially from those anticipated in such statements. WisdomTree strongly recommends that you do not place undue reliance on these forward-looking statements.

The products discussed in this document are issued by WisdomTree Issuer ICAV ("WT Issuer"). WT Issuer is an umbrella investment company with variable capital having segregated liability between its funds organised under the laws of Ireland as an Irish Collective Asset-management Vehicle and authorised by the Central Bank of Ireland ("CBI"). WT Issuer is organised as an Undertaking for Collective Investment in Transferable Securities ("UCITS") under the laws of Ireland and shall issue a separate class of shares ("Shares") representing each fund. Investors should read the prospectus of WT Issuer ("WT Prospectus") before investing and should refer to the section of the WT Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in the Shares.